OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy OncoSec to Present Strategy at Upcoming Industry Conference
SAN DIEGO, March 8, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company will be presenting its biomarker strategy with the goal of identifying and evaluating potential markers that may refine and enhance the selection of patients potentially responsive to the company's OMS ElectroImmunotherapy treatment.
With the recent approvals of immunotherapies for metastatic castrate resistant prostate cancer and non-resectable metastatic melanoma, a shift in the development paradigm of cancer immunotherapies has occurred, and at the heart of this shift is the understanding that immunotherapies result in novel patterns of antitumor response, which are delayed compared to other conventional treatments. Therefore it is evident that measurable and reproducible biomarkers must be identified for use as either prognostic or predictive tools, thus allowing investigation of its relationship with clinical outcomes. Through collaboration with Serametrix Corporation, OncoSec Medical Inc. is attempting to decipher these biomarkers early in clinical development using novel profiling assays, for its electroporation-mediated delivery of the immunotherapeutic agent Interleukin-12 (IL-12).
Michael Cross, Ph.D., M.B.A., Chief Business Officer at OncoSec, will be presenting the company's strategy at the upcoming BioMarker Partnering & Deal-Making Conference during the BioMarker Summit 2012 in San Diego, March 15-16, 2012.
Biomarker Partnering & Deal-Making Conference
Paradise Point Resort
1404 Vacation Road
San Diego, CA
March 15-16, 2012
March 15, 2012
About Global Technology Community BioMarker Summit 2012
The BioMarker Summit, held by the Global Technology Community, attracts experienced health industry decision-makers, researchers, scientists and other business professionals to a unique one-stop forum. This summit allows attendees the unique opportunity to engage in a summit that will allow them immersion into specific tracks including Biomarker Development, BioMarkers & Diagnostics, Oncology Biomarkers and Biomarker Partnering & Deal-Making.
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated